	US 12,188,058 B2
	Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
Erno Pungor, Novato, CA (US); Charles Hague, Novato, CA (US); Zhi Chen, Novato, CA (US); Melita Dvorak-Ewell, Berkeley, CA (US); Michel Claude Vellard, Novato, CA (US); and Vish Koppaka, San Rafael, CA (US)
Assigned to BIOMARIN PHARMACEUTICAL INC., Novato, CA (US)
Filed by BIOMARIN PHARMACEUTICAL INC., Novato, CA (US)
Filed on Mar. 1, 2021, as Appl. No. 17/188,994.
Application 17/188,994 is a continuation of application No. 16/783,589, filed on Feb. 6, 2020, granted, now 10,934,534.
Application 16/783,589 is a continuation of application No. 15/869,549, filed on Jan. 12, 2018, granted, now 10,563,183.
Application 15/869,549 is a continuation of application No. 14/924,405, filed on Oct. 27, 2015, granted, now 9,873,867.
Application 14/924,405 is a continuation of application No. 13/848,561, filed on Mar. 21, 2013, granted, now 9,200,264.
Application 13/848,561 is a continuation of application No. 13/371,082, filed on Feb. 10, 2012, granted, now 8,420,368.
Application 13/371,082 is a continuation of application No. 12/355,453, filed on Jan. 16, 2009, granted, now 8,128,925.
Claims priority of provisional application 61/110,246, filed on Oct. 31, 2008.
Claims priority of provisional application 61/099,373, filed on Sep. 23, 2008.
Claims priority of provisional application 61/022,179, filed on Jan. 18, 2008.
Prior Publication US 2021/0189357 A1, Jun. 24, 2021
Int. Cl. C12N 9/16 (2006.01); C12Q 1/34 (2006.01); C12Q 1/44 (2006.01); G01N 33/68 (2006.01); A61K 38/00 (2006.01)

CPC C12N 9/16 (2013.01) [C12Q 1/34 (2013.01); C12Q 1/44 (2013.01); G01N 33/6893 (2013.01); A01K 2217/075 (2013.01); A01K 2267/035 (2013.01); A61K 38/00 (2013.01); C12Y 301/06014 (2013.01); G01N 2333/924 (2013.01); G01N 2400/40 (2013.01); G01N 2500/04 (2013.01); G01N 2800/04 (2013.01)]

1 Claim

1. A method of treating a human subject suffering from Metachromatic Leukodystrophy (MLD) comprising administering to the subject in need of said lysosomal sulfatase enzyme an effective amount of said lysosomal sulfatase enzyme, wherein said lysosomal sulfatase enzyme is a recombinant human arylsulfatase A (ARSA) enzyme comprising at least 0.5 bis-phosphorylated oligomannose chains per protein chain and is produced by a CHO-derived END3 complementation group cell.